Finance Watch: HilleVax, Belite Bio Launch First Two Biopharma IPOs In Q2
Year-To-Date US First-Time Offerings Finally Hit Double Digits
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
